NIPH Clinical Trials Search

JRCT ID: jRCTs031220373

Registered date:11/10/2022

Parallel-group comparative study to evaluate the effect of high-dose nicotinamide mononucleotide (NMN) on aging

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedOlder adults who do not take medicine
Date of first enrollment17/10/2022
Target sample size62
Countries of recruitment
Study typeInterventional
Intervention(s)Participants will be randomized in 2 groups: NMN 1,250 mg (5 tablets of 250 mg) orally, once a day, 24 weeks Placebo (5 tablets) orally, once a day, 24 weeks


Primary OutcomeChange from baseline in hearing ability after 24 weeks of treatment
Secondary Outcome1) Change from baseline in the following items related to aging after 24 weeks of treatment. 1.Physical function 2. Blood tests 3. Biomarkers 4. DNA methylation age 5. Skin condition 6. Exercise tolerance assessed by the 6 minute walk test 7. Gut and oral microbiota 8. Number of mitochondria 9. Quality of Life 2) Correlation between blood NAD level and these items.

Key inclusion & exclusion criteria

Age minimum>= 65age old
Age maximumNot applicable
Include criteria1. Non-smoker 2. Aged 65 years old or older at the time of informed consent is taken 3. Male or female 4. Able to attend all scheduled visits 5. Able and willing to give written informed consent
Exclude criteria1. Taking health food 2. With severe hearing loss or wearing a hearing aid in daily life 3. Taking more than 1 hour daily exercise for more than 6 months 4. With a pacemaker 5. Taking medicine, including Chinese medicine 6. Having history of treatment for cancer, heart failure and myocardial infarction 7. With atrial fibrillation, arrhythmia, liver failure, renal failure, cerebrovascular disease, rheumatoid arthritis and other chronic diseases except diabetes, dyslipidemia and hypertension 8. Suspected of having viral hepatitis, HIV or syphilis 9. With drug allergy or with food allergy to health food related to this study 10. Participated in other clinical trials within 3 months 11. Judged as ineligible by clinical investigators

Related Information


Public contact
Name Yuriko Takaoka
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo Tokyo Japan 113-8655
Telephone +81-338155411
Affiliation The University of Tokyo Hospital
Scientific contact
Name Toshimasa Yamauchi
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo Tokyo Japan 113-8655
Telephone +81-338155411
Affiliation The University of Tokyo Hospital